Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9633815rdf:typepubmed:Citationlld:pubmed
pubmed-article:9633815lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9633815lifeskim:mentionsumls-concept:C0015176lld:lifeskim
pubmed-article:9633815lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:9633815lifeskim:mentionsumls-concept:C2936905lld:lifeskim
pubmed-article:9633815lifeskim:mentionsumls-concept:C1334064lld:lifeskim
pubmed-article:9633815lifeskim:mentionsumls-concept:C0060828lld:lifeskim
pubmed-article:9633815lifeskim:mentionsumls-concept:C2827424lld:lifeskim
pubmed-article:9633815lifeskim:mentionsumls-concept:C1709274lld:lifeskim
pubmed-article:9633815lifeskim:mentionsumls-concept:C0682380lld:lifeskim
pubmed-article:9633815pubmed:issue1lld:pubmed
pubmed-article:9633815pubmed:dateCreated1998-8-6lld:pubmed
pubmed-article:9633815pubmed:abstractTextHereditary tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a deficient activity of the enzyme fumarylacetoacetase (FAH). To investigate the molecular heterogeneity of tyrosinemia, the geographic distribution and the genotype-phenotype relationship, we have analyzed the FAH genotype of 25 HT1 patients. Mutation screening was performed by PCR amplification of exons 1-14 of the FAH gene, followed by SSCP analysis and direct sequencing of the amplified exons. Fourteen different mutations were found, of which seven were novel, viz. three missense mutations (G158D, P261L, F405H), a deletion of three nucleotides causing a deletion of serine (DEL366S) and three splice site mutations: IVS2+1(g-t), IVS6-1(g-c), IVS8-1(g-c). The splice site mutations IVS6-1(g-t) and IVS12+5(g-a) were frequently found in countries around the Mediterranean and northwestern Europe, respectively. No clear correlation between the genotype and the three major HT1 subtypes could be established.lld:pubmed
pubmed-article:9633815pubmed:languageenglld:pubmed
pubmed-article:9633815pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9633815pubmed:citationSubsetIMlld:pubmed
pubmed-article:9633815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9633815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9633815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9633815pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9633815pubmed:statusMEDLINElld:pubmed
pubmed-article:9633815pubmed:issn1059-7794lld:pubmed
pubmed-article:9633815pubmed:authorpubmed-author:BergerRRlld:pubmed
pubmed-article:9633815pubmed:authorpubmed-author:BrinkWWlld:pubmed
pubmed-article:9633815pubmed:authorpubmed-author:Poll-TheB TBTlld:pubmed
pubmed-article:9633815pubmed:authorpubmed-author:van den...lld:pubmed
pubmed-article:9633815pubmed:authorpubmed-author:Ploos van...lld:pubmed
pubmed-article:9633815pubmed:authorpubmed-author:BergmanA JAJlld:pubmed
pubmed-article:9633815pubmed:issnTypePrintlld:pubmed
pubmed-article:9633815pubmed:volume12lld:pubmed
pubmed-article:9633815pubmed:ownerNLMlld:pubmed
pubmed-article:9633815pubmed:authorsCompleteYlld:pubmed
pubmed-article:9633815pubmed:pagination19-26lld:pubmed
pubmed-article:9633815pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:meshHeadingpubmed-meshheading:9633815-...lld:pubmed
pubmed-article:9633815pubmed:year1998lld:pubmed
pubmed-article:9633815pubmed:articleTitleSpectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries.lld:pubmed
pubmed-article:9633815pubmed:affiliationDepartment of Metabolic Diseases, Wilhelmina Children's Hospital, The Netherlands.lld:pubmed
pubmed-article:9633815pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:2184entrezgene:pubmedpubmed-article:9633815lld:entrezgene